Results 191 to 200 of about 1,917,601 (292)

Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study. [PDF]

BMC Pulm Med
Huang WC, Shen YL, Cheng WC, Huang CW, Chen CH, Tu CY, Hsu WH.   +6 more
europepmc   +1 more source

Clinical Trial: Capsule Sponge as a Non‐Endoscopic Monitoring Tool in Eosinophilic Oesophagitis—A Prospective Real–World Multicentre Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Capsule sponge sampling with Endosign provides a safe, feasible and acceptable alternative to endoscopic biopsy for monitoring eosinophilic oesophagitis. In 164 paired assessments, eosinophil counts on capsule sponge cytology showed a strong correlation with endoscopic biopsy histology.
Rohith Kumar, Ayesha Rai, Kim Shaw, Erzsebet Santa, Francoise Cole, Hyesha McDonald, Pearl Baker, Lisa Mears, Anjan Dhar, Guiomar Moral‐Villarejo, Jacobo Ortiz Fernández‐Sordo, Ashraf Sanduka, Maria O'Donovan, Radina Georgieva, Sarah Killcoyne, Danielle L. Morris   +15 more
wiley   +1 more source

Beyond eosinophil depletion: long-term clinical trajectory and durability of response to benralizumab in patients with severe eosinophilic asthma and CRSwNP: an 18-month real-world study (the BANDOR study). [PDF]

Front Immunol
Bizzi E, Marra AM, Manzotti G, Gidaro A, Ortolani V, Iemoli E, Borgonovo L, Asperti C, Modica S, Greco E, Rotunno S, Yacoub MR, Ministrini S, Bini F, Germinario C, Mauro A, Paciullo F, Damanti S, Casarin F, Sculco M, Rovere Querini P.   +20 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Li Y, Li J, Yang H, Wu L.
europepmc   +1 more source

Inflammatory Mediators Associated With Corticosteroid Responsiveness During Asthma Attacks

Clinical &Experimental Allergy, EarlyView.
ABSTRACT Higher baseline sputum/serum eotaxin‐3 and serum IL‐5 levels were associated with greater FEV1 improvement following OCS during asthma attacks. Corticosteroid‐induced inflammatory modulation differed across T2 phenotypes during asthma attacks.
Carlos Celis‐Preciado, Elsa Ben Hamou Kuijpers, Mohamed‐Ilias Kourid, Simon Leclerc, Martine Duval, Dominic O. Cliche, Félix‐Antoine Vézina, Pierre Larivée, Samuel Lemaire‐Paquette, Philippe Lachapelle, Martin Klein, Simon Couillard   +11 more
wiley   +1 more source

Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma. [PDF]

Sci Rep
Xinmin P, Jinxia C, Fengyuan L.
europepmc   +1 more source

Functional respiratory imaging reveals early structural and functional airway responses to benralizumab in severe eosinophilic asthma. [PDF]

BMJ Open Respir Res
Conemans L, Deng Q, Simons SO, Franssen FME, Spruit MA, Hajian B.   +5 more
europepmc   +1 more source

Benralizumab in severe eosinophilic asthma: a comprehensive systematic review and meta-analysis of randomized controlled trials evaluating lung function, asthma control, and safety outcomes. [PDF]

Syst Rev
Al Mutair A, Alabbasi Y, Alharbi HF, Alyami H, Al-Shammari HM, Al-Omari AA, Bomozah EA, Aljarameez F, Daniyal M.   +8 more
europepmc   +1 more source

Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain. [PDF]

J Clin Med
García-Moguel I, Agüero Calvo J, Betancor Pérez D, Carretero Gracia JÁ, Díaz-Campos RM, Fernández Martínez de Septien C, Gómez-Bastero Fernández A, Hernández Galván Y, Lloret-Queraltó JA, Lluch Tortajada I, Malanda NM, Martín-García C, Martínez Mesa Á, Martínez-Moragon E, Medina Gallardo JF, Padilla-Galo A, Pérez Chica G, Plasencia García I, Prieto Montaño P, Puchaes Manchón C, Romero Ribate D, Valverde-Monge M, Zamarro Parra MS, Sanchez-Trincado JL, Nuevo J, Luzon E, Velasco-Garrido JL.   +26 more
europepmc   +1 more source